ZUG, Switzerland and CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in May.
Bank of America Securities 2023 Health Care Conference
Date: Tuesday, May 9, 2023
Time: 10:40 a.m. PT
JMP Securities Life Sciences Conference
Date: Monday, May 15, 2023
Time: 11:30 a.m. ET
A live webcast of the fireside chats will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
Investor Contact:
Susan Kim
+1-617-307-7503
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Rachel Eides
+1-617-315-4493
This email address is being protected from spambots. You need JavaScript enabled to view it.\
| Last Trade: | US$38.36 |
| Daily Change: | -0.49 -1.26 |
| Daily Volume: | 1,471,991 |
| Market Cap: | US$3.270B |
January 08, 2025 December 09, 2024 November 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
